TL;DR:

  • Clinical evidence supports VR’s effectiveness in palliative care for reducing pain perception, procedural anxiety, and psychological distress — gating mechanisms in the brain that limit pain and anxiety processing when attention is absorbed in immersive environments
  • UK hospices including Marie Curie and Sue Ryder have run VR programmes; adoption is growing as headsets have become lighter, more accessible to older users, and easier to clean hygienically
  • The leading applications are nature environments, guided meditation, virtual travel, and family connection experiences — not gaming or entertainment but experiences designed specifically for clinical populations with limited mobility

Palliative care deals with a specific and difficult problem: how do you improve quality of life for people with serious illness when treatment options are limited or exhausted? Pain management, anxiety reduction, and psychological wellbeing become primary goals rather than disease modification. VR turns out to address several of these goals through mechanisms that are relatively well understood.

The core mechanism is attentional: when a patient is fully immersed in a compelling virtual environment, the brain allocates attentional resources to processing the sensory input. This directly competes with the processing of pain signals and anxiety — a well-established phenomenon called attentional distraction, but amplified to a degree that simple distraction (music, TV) doesn’t reliably achieve. This isn’t a placebo effect in the dismissive sense; the measurable reduction in pain scores during VR use is real and clinically meaningful for a significant proportion of patients.

The Clinical Evidence

The evidence base for VR in pain management has strengthened considerably since early studies in burn wound care (the SnowWorld research at the University of Washington remains influential). In palliative care specifically, research has focused on three applications:

Procedural pain and anxiety: Palliative patients frequently undergo painful or distressing procedures — port access, wound care, medication adjustments. VR used during these procedures consistently shows reduction in real-time pain scores and patient-reported anxiety. The effect is large enough to reduce analgesic requirements in some protocols.

Background pain and anxiety management: Longer VR sessions (20-40 minutes) using calming natural environments show reductions in pain scores and anxiety levels that persist for 30-60 minutes after the headset is removed. The mechanism here likely involves reduction in cortisol and sympathetic nervous system activity — physiological changes, not just reported comfort.

Psychological wellbeing: Depression, existential distress, and feelings of isolation are common in palliative care settings. VR experiences designed around positive psychology — reconnecting with meaningful places, accessing nature, completing “bucket list” experiences virtually — show improvements in mood and reported quality of life in small-scale trials. AppliedVR’s studies (conducted primarily in the US) and Oxford VR’s UK-based research both contribute to this literature.

The limitations are important to name: most studies have small sample sizes, and palliative populations are heterogeneous in ways that make generalisation difficult. VR is not effective for all patients, and some people — those with nausea susceptibility, claustrophobia, cognitive impairment affecting comprehension of the experience, or simply no interest — don’t benefit or tolerate it. The clinical picture is “helpful for a meaningful proportion of patients” not “universally effective.”

What UK Hospices Are Using It For

Marie Curie hospices have run VR programmes using the Oculus Quest (now Meta Quest) platform with curated content libraries. Experiences include guided nature walks through Scottish highlands, virtual visits to landscapes patients have mentioned as meaningful, and ocean environments with ambient sound.

The experience design for this population is deliberately not gaming or high-stimulation content. Software specifically built for clinical use — from developers like Psious, Oxford VR’s clinical library, and XRHealth — is designed around low motion, high visual quality, and content that evokes calm or positive emotion rather than excitement. Typical session structure involves a staff member present, a brief orientation to the headset, and a choice of environment.

Sue Ryder has integrated VR into bereavement support programmes alongside clinical care — an application that extends beyond patient use to supporting family members during and after a loved one’s final period.

Practical Considerations for Palliative Settings

Headset selection: Older patients often have difficulty with complex controls. The Meta Quest 3S and Pico 4 are the most commonly used headsets in UK clinical settings by 2026 — lighter than earlier devices, with simplified interfaces. Staff typically operate the headset selection and initiation rather than the patient.

Hygiene: VR headsets used across multiple patients require robust cleaning protocols. Disposable silicone face cushion covers are now standard in clinical VR deployments — they’re low cost, single-use, and prevent the cross-contamination concerns that were a significant barrier to adoption in earlier years.

Contraindications: VR is generally avoided for patients with active nausea (common in some palliative conditions and medication regimes), severe cognitive impairment, significant visual impairment that prevents meaningful engagement, or acute respiratory distress where headset use is uncomfortable. Assessment before each session is standard practice.

Staff training: Clinical staff need brief training on headset operation, contraindication assessment, and responding to patient discomfort. This doesn’t require technical expertise — most UK hospice programmes provide half-day training for all relevant staff.

Digital Legacy and Family Connection

One application that sits outside the clinical pain/anxiety domain is digital legacy and family connection. Some hospices offer sessions in which patients explore meaningful places virtually — their childhood home’s neighbourhood, a holiday destination — and record audio or video reflections while immersed in those environments. These recordings become part of a digital legacy for family members.

Separately, volumetric capture technology (used commercially in entertainment) is beginning to appear in end-of-life contexts in the US, allowing a dying person to be captured in 3D and have interactive conversations with family members after death. This technology is nascent and raises genuine ethical questions about consent and use, but it represents the direction some organisations are exploring.

Getting Started in a UK Hospice

For palliative care teams interested in introducing VR, the Hospice UK digital health workstream has published implementation guidance. Practical starting points include connecting with Marie Curie’s digital team, who have shared learnings from their programme, and contacting XRHealth or Psious about clinical licensing for their content libraries.

The capital cost is lower than many clinical technology purchases — a pair of Meta Quest 3S headsets with clinical face covers, a charging station, and a content licence runs under £2,000. The barrier is less financial than it is clinical governance, training, and integration into care pathways. Both of those barriers are more surmountable than they were three years ago.